托珠单抗与标准治疗对COVID-19肺炎住院患者临床恶化的影响:一项随机临床试验
这项前瞻性开放标签随机临床试验在意大利24家医院纳入126例COVID-19肺炎住院患者,随机分为托珠单抗组(60例,静脉8 mg/kg最大800 mg,随机后8小时内给药,12小时后第二剂)和标准治疗组(66例)。主要复合终点为进入ICU接受有创机械通气、全因死亡或Pao2/Fio2<150 mmHg的临床恶化,随机后14天内托珠单抗组28.3%(17/60)vs 标准治疗组27.0%(17/63)出现临床恶化,率比1.05(95%CI 0.59-1.86)。托珠单抗组与标准治疗组分别有2例和1例在30天内死亡,6例和5例插管。试验因中期分析显示无效而提前终止。
要点
- 在COVID-19肺炎且Pao2/Fio2 200-300 mmHg的住院成人中,托珠单抗组14天内临床恶化28.3%(17/60),标准治疗组27.0%(17/63),率比1.05(95%CI 0.59-1.86)。
- 托珠单抗给药方案为静脉8 mg/kg(最大800 mg),随机后8小时内首剂,12小时后第二剂;标准治疗组恶化后可用托珠单抗作为挽救治疗。
- 30天内死亡:托珠单抗组2例,标准治疗组1例;插管:托珠单抗组6例,标准治疗组5例。
- 试验因中期分析显示无效而提前终止。
- 作者结论认为,在此类患者中托珠单抗较标准治疗未观察到对疾病进展的获益,需进一步盲法安慰剂对照随机临床试验确认结果并评估不同疾病阶段的应用。
适用人群与场景
- 住院成人COVID-19肺炎患者,经鼻咽拭子聚合酶链反应确诊,影像学证实肺炎,Pao2/Fio2比值200-300 mmHg,且具备炎症表型(发热和C反应蛋白升高)。
- 2020年3月31日至6月11日在意大利24家医院住院并随机化的患者。
诊断标准与关键阈值
- COVID-19确诊:聚合酶链反应法鼻咽拭子阳性。
- 肺炎:影像学检查证实。
- Pao2/Fio2比值在200至300 mmHg之间。
- 炎症表型:发热和C反应蛋白升高。
处置流程与药物剂量
- 托珠单抗组:随机后8小时内静脉给予托珠单抗8 mg/kg(最大800 mg),12小时后给予第二剂。
- 对照组:按各临床中心方案给予支持治疗,直至临床恶化后可接受托珠单抗作为挽救治疗。
研究设计与关键结果
- 研究设计:前瞻性、开放标签、随机临床试验,在意大利24家医院纳入126例患者(托珠单抗组60例,对照组66例),中位年龄60.0岁(四分位距53.0-72.0),男性77/126(61.1%);3例退出研究,123例纳入意向性治疗分析。
- 主要复合终点(进入ICU接受有创机械通气、全因死亡或Pao2/Fio2<150 mmHg的临床恶化,以先发生者为准):随机后14天内托珠单抗组17/60(28.3%)vs 标准治疗组17/63(27.0%),率比1.05(95%CI 0.59-1.86)。
- 30天内死亡:托珠单抗组2例,标准治疗组1例;插管:托珠单抗组6例,标准治疗组5例。
- 试验因中期分析显示无效而提前终止。
证据类型、等级与局限
- 证据类型:前瞻性、开放标签、随机临床试验。
- 局限性:试验因中期分析显示无效而提前终止;作者指出需进一步盲法、安慰剂对照随机临床试验确认结果并评估托珠单抗在不同疾病阶段的应用。
对床旁实践的改变
- 作者结论认为,在COVID-19肺炎且Pao2/Fio2比值200-300 mmHg的住院成人中,托珠单抗较标准治疗未观察到对疾病进展的获益。
- 作者建议需进一步盲法、安慰剂对照随机临床试验确认结果并评估托珠单抗在不同疾病阶段的应用。
指南或共识出处
- ClinicalTrials.gov Identifier: NCT04346355;EudraCT Identifier: 2020-001386-37。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The coronavirus disease 2019 (COVID-19) pandemic is threatening billions of people worldwide. Tocilizumab has shown promising results in retrospective studies in patients with COVID-19 pneumonia with a good safety profile.
OBJECTIVE: To evaluate the effect of early tocilizumab administration vs standard therapy in preventing clinical worsening in patients hospitalized with COVID-19 pneumonia.
DESIGN, SETTING, AND PARTICIPANTS: Prospective, open-label, randomized clinical trial that randomized patients hospitalized between March 31 and June 11, 2020, with COVID-19 pneumonia to receive tocilizumab or standard of care in 24 hospitals in Italy. Cases of COVID-19 were confirmed by polymerase chain reaction method with nasopharyngeal swab. Eligibility criteria included COVID-19 pneumonia documented by radiologic imaging, partial pressure of arterial oxygen to fraction of inspired oxygen (Pao2/Fio2) ratio between 200 and 300 mm Hg, and an inflammatory phenotype defined by fever and elevated C-reactive protein.
INTERVENTIONS: Patients in the experimental arm received intravenous tocilizumab within 8 hours from randomization (8 mg/kg up to a maximum of 800 mg), followed by a second dose after 12 hours. Patients in the control arm received supportive care following the protocols of each clinical center until clinical worsening and then could receive tocilizumab as a rescue therapy.
MAIN OUTCOME AND MEASURES: The primary composite outcome was defined as entry into the intensive care unit with invasive mechanical ventilation, death from all causes, or clinical aggravation documented by the finding of a Pao2/Fio2 ratio less than 150 mm Hg, whichever came first.
RESULTS: A total of 126 patients were randomized (60 to the tocilizumab group; 66 to the control group). The median (interquartile range) age was 60.0 (53.0-72.0) years, and the majority of patients were male (77 of 126, 61.1%). Three patients withdrew from the study, leaving 123 patients available for the intention-to-treat analyses. Seventeen patients of 60 (28.3%) in the tocilizumab arm and 17 of 63 (27.0%) in the standard care group showed clinical worsening within 14 days since randomization (rate ratio, 1.05; 95% CI, 0.59-1.86). Two patients in the experimental group and 1 in the control group died before 30 days from randomization, and 6 and 5 patients were intubated in the 2 groups, respectively. The trial was prematurely interrupted after an interim analysis for futility.
CONCLUSIONS AND RELEVANCE: In this randomized clinical trial of hospitalized adult patients with COVID-19 pneumonia and Pao2/Fio2 ratio between 200 and 300 mm Hg who received tocilizumab, no benefit on disease progression was observed compared with standard care. Further blinded, placebo-controlled randomized clinical trials are needed to confirm the results and to evaluate possible applications of tocilizumab in different stages of the disease.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04346355; EudraCT Identifier: 2020-001386-37.
参考来源
- Salvarani C, Dolci G, Massari M, et al. Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial. JAMA Intern Med. 2021. PMID: 33080005. doi:10.1001/jamainternmed.2020.6615
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。